跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT03961009
NCT03961009已完成3 期

A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety and Pharmacokinetics of Kedrion Intravenous Immunoglobulin (IVIg) 10% in Primary Immunodeficiency Disease (PID) Patients

Kedrion S.p.A.22 个研究点 分布在 1 个国家目标入组 47 人开始时间: 2019年4月30日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
47
试验地点
22
主要终点
Incidence Rate of Acute Serious Bacterial Infections (ABSIs)
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验相关资讯

研究概览

简要总结

The purpose of this study was to assess efficacy and safety of Kedrion Immunoglobulin 10% (KIg10) in participants with Primary Immunodeficiency (PID).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
2 Years 至 70 Years（Child, Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •Written informed consent/assent obtained from participant/participant's parent(s) or legally acceptable representative indicating that they understand the purpose of and procedures required for the study and are willing to participate in it.
  • •Confirmed clinical diagnosis of a PID, requiring treatment with IVIg and have documented agammaglobulinemia (defined as the total absence of one or more classes of antibodies) or hypogammaglobulinemia (defined as low levels of one or more classes [that is at least 2 standard deviations under the mean level per age])
  • •Male or female, ages 2 to 70 years at screening
  • •Received 200 to 800 mg/kg of a commercially available IVIg therapy in the range of 21- or 28-day intervals (±3 days or ±4 days, respectively) for at least 3 infusion cycles prior to screening
  • •At least 2 documented IgG trough levels while receiving an IVIg, of greater than or equals to (>=) 6 gram per liter (g/L) obtained at 2 infusion cycles within 12 months (1 must be within 6 months) prior to Informed Consent Form (ICF) signature
  • •Participant is willing to comply all requirements of the protocol.
  • •Females of child-bearing potential with a negative urine pregnancy test and who agree to employ adequate birth control measures during the study
  • •Authorization to access personal health information
  • •Participant previously participating in a clinical trial with another experimental IVIg may be enrolled if they have received stable commercially available IVIg therapy for at least 3 infusion cycles (21 or 28 days) prior to screening
  • •Participant currently on treatment with any subcutaneous immunoglobulin (SCIG) can be enrolled if they are switched to stable commercially available IVIg therapy for at least 3 infusion cycles (21 or 28 days) prior to screening

排除标准

  • •Newly diagnosed PID and and naïve to IgG replacement therapy
  • •Dysgammaglobulinemia (defined as a deficiency in one or more classes of antibodies, but not severe enough to require substitutive therapy) or isolated IgG subclass deficiency or profound primary T-cell deficiency (defined as the absence or severe reduction of T lymphocytes [CD3+ <300 cells per cubic millimeter (cell/mm3)] and an absent or particularly low proliferative response [10% of the lower normal range] to phytohaemagglutinin P [PHA])
  • •Has history of severe or serious reactions or hypersensitivity to IVIg or other injectable forms of IgG
  • •Has history of thrombotic events (including deep vein thrombosis, cerebrovascular accident, pulmonary embolism, transient ischemic attacks, or myocardial infarction), as defined by at least 1 event in participant's lifetime
  • •Has IgA deficiency with documented antibodies to IgA
  • •Have received blood products that have not undergone viral inactivation measures within 12 months prior to Informed Consent Form (ICF) signature
  • •Has significant protein losing enteropathy, nephrotic syndrome, or lymphangiectasia
  • •Has an acute infection as documented by culture or diagnostic imaging and/or a body temperature >= 38 degree Celsius (°C) (>=100.4 degree Fahrenheit (°F) within 7 days prior to screening
  • •Has acquired immunodeficiency syndrome (AIDS) and/or hepatitis B/C active disease at ICF signature
  • •Has levels of Alanine aminotransferase (ALT) or aspartate aminotransferase (AST), 2.5 times of the upper limit of normal for the laboratory designated for the study
  • •Using an implanted venous access device
  • •Has profound anemia (haemoglobin less than10 gram per deciliter [g/dl]) or persistent severe neutropenia (<= 1000 neutrophils per millimeter cube (mm^3) or lymphopenia of less than 500 cells per microliter
  • •Have severe chronic condition such as renal failure (creatinine concentration > 2.0 times the upper limit of normal) with proteinuria, congestive heart failure (New York Heart Association III/IV), cardiomyopathy, cardiac arrhythmia associated with thromboembolic events (e.g., atrial fibrillation), unstable or advanced ischemic heart disease, hyper viscosity, or any other condition that the Investigator believes is likely to interfere with evaluation of the study drug or with satisfactory conduct of the trial. Normal values for serum creatinine are the following: a) Female (18+ years): 45 - 84 micromole per liter (mcmol/L) or 0.51 - 0.95 milligrams per deciliter (mg/dl); b) Male (18+ years): 59 - 103 mcmol/L or 0.67 - 1.17 mg/dl
  • •Has history of a malignant disease other than properly treated carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin within 24 months prior to ICF signature
  • •Has history of pharmacoresistant epilepsy or multiple episodes of migraine (defined as at least 1 episode within 6 months of ICF signature) not completely controlled by medication
  • •Participants must not be receiving steroids (oral or parenteral daily dose of >= 0.15 milligram per kilogram per day (mg/kg/day) of prednisone or equivalent) or other immunosuppressive drugs or chemotherapy
  • •Females who are pregnant, breast feeding or planning a pregnancy during the course of the study. Women who become pregnant during the study will be withdrawn from the study
  • •Has participated in another clinical study within 3 weeks prior to study ICF signature
  • •Has history of drug or alcohol abuse within the 6 months before screening
  • •Has Employed or a direct relative of an employee of the CRO, the study site, or the Sponsor
  • •Previously treated under this protocol
  • •Unable to provide informed consent or provide informed consent by a legally authorized representative

研究组 & 干预措施

Kedrion IVIG 10%

Experimental

Participants received intravenous infusion of Kedrion IVIG 10% at a dose of 200 to 800 milligrams per kilogram (mg/kg) body weight on every 21 or 28 days for period of 48 weeks.

干预措施: Kedrion IVIG 10% (Biological)

结局指标

主要结局

Incidence Rate of Acute Serious Bacterial Infections (ABSIs)

时间窗: Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule)

Incidence rate was defined as the mean number of acute serious bacterial infections (bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, visceral abscess, osteomyelitis/septic arthritis) per participant-year according to pre-specified criteria.

次要结局

  • Number of Infusions With One or More Infusion Associated Adverse Events (AEs)(Baseline up to Week 52)
  • Serum Immunoglobulin G (IgG) Trough Levels(At baseline, Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule))
  • Immunoglobulin G (IgG) Subclasses Levels (IgG1, IgG2, IgG3, IgG4)(At baseline, Weeks 16, 32 and 48 (28-day dosing schedule); Weeks 18, 30, 48 (21-day dosing schedule))
  • Number of Participants With Total Immunoglobulin G (IgG) Trough Levels Less Than or Equal to (<=) 6 Grams/Liter (g/L) Criteria(Up to 12 months)
  • Number of Infusions With Decreased Infusion Rate Due to Adverse Events (AEs)(Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule))
  • Number of Participants With Positive Urine Hemosiderin Test(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule))
  • Duration of Participants Hospitalization Due to Infection(Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule))
  • Anti-Tetanus Toxoid Antibody Levels(Baseline, Weeks 16, 32 and 48 (28-day dosing schedule); Weeks 18, 30, 48 (21-day dosing schedule))
  • Anti-Pneumococcal Capsular Polysaccharide Antibody Levels(Baseline, Weeks 16, 32 and 48 (28-day dosing schedule); Weeks 18, 30, 48 (21-day dosing schedule))
  • Anti-Measles Antibody Levels(Baseline, Weeks 16, 32 and 48 (28-day dosing schedule); Weeks 18, 30, 48 (21-day dosing schedule))
  • Anti-Haemophilus Influenza Type B Antibody Levels(Baseline, Weeks 16, 32 and 48 (28 -day dosing schedule); Weeks 18, 30, 48 (21-day dosing schedule))
  • Incidence Rate of Any Infection Other Than Acute Serious Bacterial Infections(Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule))
  • Duration of Any Infection Other Than Acute Serious Bacterial Infections(Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule))
  • Incidence Rate of Fever Episodes(Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule))
  • Duration of Fever Episodes in Participants(Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule))
  • Duration of Overall Participants Hospitalization(Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule))
  • Incidence Rate of Antibiotics Episodes for Treatment of Any Kind of Infections(Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule))
  • Duration of Participants on Antibiotics for Treatment of Any Kind of Infection(Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule))
  • Duration of Missed School/Work/Other Major Activities Due to Infections(Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule))
  • Pediatric Quality of Life Inventory (PedsQL) Score(Baseline, Week 24 (21-day dosing schedule and 28-day dosing schedule), Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule))
  • Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs(Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule))
  • Number of TEAEs and Serious TEAEs(Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule))
  • Number of Drug Related Infusion Adverse Events (AEs)(Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule))
  • Percentage of Participants Who Experienced at Least One Drug Related Infusion Adverse Events (AEs)(Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule))
  • Number of Participants With Clinically Significant Changes From Baseline in Vital Signs(Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule))
  • Number of Participants With Clinically Significant Changes From Baseline in Physical Examinations(Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule))
  • Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters(Baseline up to Week 51 (21-day dosing schedule) and Week 52 (28-day dosing schedule))
  • Number of Participants With Positive Coomb's Test at Week 16 (28-day Dosing Schedule) and Week 18 (21-day Dosing Schedule)(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule))
  • Number of Participants With Abnormal Plasma-free Haemoglobin Level(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule))
  • Number of Participants With Abnormal Serum Haptoglobin Level(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule))
  • Maximum Observed Serum Concentration (Cmax) of Total Immunoglobulin G (IgG)(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Elimination Half-Life (t1/2) of Total IgG(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of Total IgG(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Area Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Total IgG(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Area Under the Serum Concentration-Time Curve During a Dosing Interval (AUCtau) of Total IgG(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Volume of Distribution (Vd) of Total IgG(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Steady State Clearance (CLss) of Total IgG(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Minimum Observed Serum Concentration (Cmin) of Total IgG(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Elimination Half-Life (t1/2) of Antigen-Specific Tetanus Toxoid Antibodies(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Percentage Peak Trough Fluctuation of Total IgG(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Steady State Clearance (CLss) of Antigen-Specific Tetanus Toxoid Antibodies(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Time to Reach the Maximum Serum Concentration (Tmax) of Total IgG(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Elimination Rate Constant (Kel) of Total IgG(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Average Concentration of Total IgG Over the Dosing Interval (Cavg)(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Area Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Antigen-Specific Tetanus Toxoid Antibodies(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Volume of Distribution (Vd) of Antigen-Specific Tetanus Toxoid Antibodies(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Area Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Antigen-Specific Haemophilus Influenza Type B Antibodies(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Area Under the Serum Concentration-Time Curve During a Dosing Interval (AUCtau) of Antigen-Specific Haemophilus Influenza Type B Antibodies(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Volume of Distribution (Vd) of Antigen-Specific Haemophilus Influenza Type B Antibodies(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Minimum Observed Serum Concentration (Cmin) of Antigen-Specific Haemophilus Influenza Type B Antibodies(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Maximum Observed Serum Concentration (Cmax) of Antigen-Specific Tetanus Toxoid Antibodies(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of Antigen-Specific Tetanus Toxoid Antibodies(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Area Under the Serum Concentration-Time Curve During a Dosing Interval (AUCtau) of Antigen-Specific Tetanus Toxoid Antibodies(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Minimum Observed Serum Concentration (Cmin) of Antigen-Specific Tetanus Toxoid Antibodies(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Time to Reach the Maximum Serum Concentration (Tmax) of Antigen-Specific Tetanus Toxoid Antibodies(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Elimination Rate Constant (Kel) of Antigen-Specific Tetanus Toxoid Antibodies(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Average Concentration of Antigen-Specific Tetanus Toxoid Antibodies Over the Dosing Interval (Cavg)(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Percentage Peak Trough Fluctuation of Antigen-Specific Tetanus Toxoid Antibodies(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Maximum Observed Serum Concentration (Cmax) of Antigen-Specific Haemophilus Influenza Type B Antibodies(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Elimination Half-Life (t1/2) of Antigen-Specific Haemophilus Influenza Type B Antibodies(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of Antigen-Specific Haemophilus Influenza Type B Antibodies(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Steady State Clearance (CLss) of Antigen-Specific Haemophilus Influenza Type B Antibodies(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Time to Reach the Maximum Serum Concentration (Tmax) of Antigen-Specific Haemophilus Influenza Type B Antibodies(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Terminal Elimination Rate Constant (Lambda z) of Antigen-Specific Haemophilus Influenza Type B Antibodies(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Average Concentration of Antigen-Specific Haemophilus Influenza Type B Antibodies Over the Dosing Interval (Cavg)(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Percentage Peak Trough Fluctuation of Antigen-Specific Haemophilus Influenza Type B Antibodies(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Maximum Observed Serum Concentration (Cmax) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Elimination Half-Life (t1/2) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Area Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Area Under the Serum Concentration-Time Curve During a Dosing Interval (AUCtau) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Volume of Distribution (Vd) of of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Steady State Clearance (CLss) of Anti-pneumococcal Capsular Polysaccharide Antibodies (Overall SP Serotypes)(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Minimum Observed Serum Concentration (Cmin) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Time to Reach the Maximum Serum Concentration (Tmax) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Elimination Rate Constant (Kel) of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Average Concentration of Anti-pneumococcal Capsular Polysaccharide the Dosing Interval (Cavg) (Overall SP Serotypes)(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)
  • Percentage Peak Trough Fluctuation of Anti-pneumococcal Capsular Polysaccharide (Overall SP Serotypes)(At Week 16 (28-day dosing schedule) and Week 18 (21-day dosing schedule), 10 to 30 minutes pre-infusion, 30 minutes, 2, 24, 72, 168, 336, 504, 672 hours post infusion)

研究者

发起方
Kedrion S.p.A.
申办方类型
Industry
责任方
Sponsor

研究点 (22)

Loading locations...

相似试验

进行中（未招募）
3 期
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)Primary Immunodeficiency Disease
NCT04944979Kedrion S.p.A.30
已完成
3 期
Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)Primary ImmunodeficiencyAgammaglobulinemiaHypogammaglobulinemiaAntibody Deficiency
NCT01581593Kedrion S.p.A.45
招募中
3 期
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Chronic Inflammatory Demyelinating Polyneuropathy
NCT06752356Kedrion S.p.A.161
已完成
3 期
Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10Immune Thrombocytopenic Purpura
NCT00168038CSL Behring58
招募中
3 期
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal CancerEsophageal Squamous Cell Carcinoma
NCT06194734Beijing Konruns Pharmaceutical Co., Ltd.490

相关资讯